A guide to Irish regulated funds
This article explains the ins and outs of investment funds in Ireland.
This article explains the ins and outs of investment funds in Ireland.
This article briefly discusses the necessity for lawyers to have an appropriate level of financial and accounting knowledge in order to understand and articulate financial principles.
This resource was originally published on the website of Eversheds Sutherland on September 13, 2023.
This guide provides an overview of cryptoasset regulation (prior to the introduction of MiCA), focussing at this point on European jurisdictions, both inside and outside the EU. It summarizes the regulations applying to the main activities performed by cryptoasset service providers and the requirements of the licensing regimes, including time and cost.
The article provides a brief overview of open finance, a practice that allows third party service providers access to consumers’ financial data from banks and financial institutions using secure application programming interfaces (APIs).
This guide provides an overview of the environmental, social and governance (ESG) disclosure obligations within the Asia Pacific (APAC) region.
This article provides a summary of the European Commission’s key proposals under a third Payment Services Directive (PSD3), the EU Payment Services Regulation (PSR) and the EU open finance regime.
This article discusses the US Drug Enforcement Agency's (DEA) new regulation temporarily extending the “full set” of COVID-19 waivers for prescribing controlled substances via telemedicine.
Originally published by Foley & Lardner LLP on May 11, 2023.
This article discusses the friendly-PC model, which is a common structure designed to comply with state corporate practice of medicine doctrines. The friendly-PC model involves a professional service corporation (PSC) conducting a medical practice in affiliation with a management services organization (MSO).
Although the friendly-PC model may be a solution to the corporate practice of medicine doctrine, it can create unintended consequences for employee benefit plans sponsored by the PSC and MSO.
This article discusses the U.S. Food and Drug Administration's draft guidance regarding the implementation of Decentralized Clinical Trials (DCTs) for drugs, biological products, and devices.
This article discusses the U.S. Food and Drug Administration's draft guidance on artificial intelligence/machine learning (AI/ML)-enabled devices.
The draft guidance — "Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions" — was issued on April 3, 2023.